Stanley Capital
menu
  • About Us
  • Team
  • ESG
  • Approach
  • Active Value Creation
  • Investments
  • News

Category Archives: S&P Global

PDL BioPharma closes sale of Noden business to Stanley Capital

4

Posted byadminDecember 5, 2021December 30, 2021Posted inS&P GlobalLeave a comment on PDL BioPharma closes sale of Noden business to Stanley Capital
Stanley Capital
© 2021 Stanley Capital Partners LLP

The contents of this website are communicated by, and the property of, Stanley Capital Partners LLP. Stanley Capital Partners LLP is an appointed representative of Umbra Capital Partners LLP which is authorised and regulated by the Financial Conduct Authority. This website is directed at persons who fall within the definition of ‘professional clients’ or ‘eligible counterparties’ as defined in the rules of the Financial Conduct Authority of the United Kingdom.

The information and opinions contained on this website are subject to updating and verification and may be subject to amendment. No representation, warranty, or undertaking, express or limited, is given as to the accuracy or completeness of the information or opinions contained on this website by Stanley Capital Partners LLP or its members. No liability is accepted by such persons for the accuracy or completeness of any information or opinions. As such, no reliance may be placed for any purpose on the information and opinions contained in this document.

The value of investments and any income generated may go down as well as up and is not guaranteed. Historical track record verified and audited. Past performance is not necessarily a guide to future performance.

Stanley Capital Partners LLP is incorporated in England and has registered number OC438675. Its registered office is at 5th Floor, 1 Old Queen Street, London, SW1H 9JA.

Terms of Use

CONTACT US

info@stanley-capital.com
  • linked-in
Joining Our Mailing List

Join our mailing list